Filtered By:
Condition: Thrombosis
Cancer: Cancer
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 663 results found since Jan 2013.
Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected data
CONCLUSION: Concordance between datasets was lower than anticipated and the HSD used could not straightforwardly replace current trial practices, nor directly identify protocol-defined CVS events. Further work is required to improve the quality of HSD and consider event definitions when designing clinical trials incorporating HSD.PMID:36933612 | DOI:10.1016/j.cct.2023.107162
Source: Clinical Lung Cancer - March 18, 2023 Category: Cancer & Oncology Authors: Archie Macnair Matthew Nankivell Macey L Murray Stuart D Rosen Sally Appleyard Matthew R Sydes Sylvia Forcat Andrew Welland Noel W Clarke Stephen Mangar Howard Kynaston Roger Kockelbergh Abdulla Al-Hasso John Deighan John Marshall Mahesh Parmar Ruth E Lan Source Type: research
Venous thromboembolism in patients with idiopathic pulmonary fibrosis, based on nationwide claim data
CONCLUSION: Ischemic heart disease, ischemic stroke, and malignancy, especially lung cancer, were related to higher HR for VTE in IPF.PMID:36846942 | DOI:10.1177/17534666231155772
Source: Adv Data - February 27, 2023 Category: Epidemiology Authors: Jang Ho Lee Hoon Hee Lee Hyung Jun Park Seonok Kim Ye-Jee Kim Jae Seung Lee Ho Cheol Kim Source Type: research
Modulation of vulvovaginal atrophy (VVA) by Gelam honey in bilateral oophorectomized rats
In conclusion, the protein and gene expression changes in the vagina by Gelam honey had reduced the occurrence of vaginal atrophy in surgically-induced menopause models.
Source: Frontiers in Endocrinology - February 27, 2023 Category: Endocrinology Source Type: research
Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population
Int J Biol Macromol. 2023 Feb 7:123586. doi: 10.1016/j.ijbiomac.2023.123586. Online ahead of print.ABSTRACTA high level of lipoprotein (a) in the plasma has been associated with a variety of cardiovascular diseases and is considered to be an independent predictor of some other diseases. Based on recent studies, the concentration levels of Lp(a) in the Chinese population exhibit a distinctive variation from other populations. In the Chinese population, a high level of Lp(a) indicates a higher incidence of revascularization, platelet aggregation, and thrombogenicity following PCI. Increased risk of atherosclerotic cardiovasc...
Source: International Journal of Biological Macromolecules - February 9, 2023 Category: Biochemistry Authors: Zubair Hussain Hongcai Liu Junaid Iqbal Hou-De Zhou Source Type: research
Cumulative Incidence of Thromboembolism and Prognostic Impact of Stroke in < em > BRAF < /em > V600E-mutant Non-small-cell Lung Cancer
CONCLUSION: A substantial proportion of patients with BRAF V600E-mutant lung cancer experienced thromboembolism during their disease course. CRS of undetermined source may predict a worse prognosis in this population.PMID:36697098 | DOI:10.21873/anticanres.16237
Source: Cell Research - January 25, 2023 Category: Cytology Authors: Sho Yamada Akimasa Sekine Eri Hagiwara Yoko Onodera Erina Tabata Satoshi Ikeda Hideya Kitamura Tomohisa Baba Shigeru Komatsu Takashi Ogura Source Type: research
Stroke mortality in cancer survivors: A population-based study in Japan
The association between cancer survivors and stroke deaths remains unclear. We aimed to evaluate the risk of fatal stroke in patients with cancer.
Source: Thrombosis Research - January 9, 2023 Category: Hematology Authors: Yasufumi Gon, Ling Zha, Tsutomu Sasaki, Toshitaka Morishima, Yuko Ohno, Hideki Mochizuki, Tomotaka Sobue, Isao Miyashiro Source Type: research
Impact of stroke on survival in patients with cancer
Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), are significant concerns for patients with cancer as they can interrupt or delay essential cancer treatments and worsen outcomes [1]. Previous studies have suggested that VTE is associated with an increased risk of mortality in patients with cancer [2 –5]. Meanwhile, few studies have investigated the relationship between ATE and outcomes in patients with cancer. Grilz et al. assessed the effect of ATE on 2-year survival in such patients and reported that ATE was associated with a 3.2-fold increased risk of all-cause mortality [6].
Source: Thrombosis Research - January 6, 2023 Category: Hematology Authors: Yasufumi Gon, Tsutomu Sasaki, Tomohiro Kawano, Shuhei Okazaki, Kenichi Todo, Toshihiro Takeda, Yasushi Matsumura, Hideki Mochizuki Tags: Letter to the Editors-in-Chief Source Type: research
Which DOAC Is Cost-Effective in Cancer-Associated Thrombosis? Which DOAC Is Cost-Effective in Cancer-Associated Thrombosis?
Until recently, clinicians had little evidence to guide their decisions about the most effective and safe treatment for the oldest patients with atrial fibrillation and recent stroke.Medscape Medical News
Source: Medscape Cardiology Headlines - January 4, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Breakfast Type and Cardiovascular Mortality: The Japan Collaborative Cohort Study
CONCLUSION: Compared to Japanese breakfast, mixed Japanese-Western breakfast may have a protective role in cardiovascular mortality whereas skipping breakfast may harm cardiovascular health.PMID:36543187 | DOI:10.5551/jat.63564
Source: Journal of Atherosclerosis and Thrombosis - December 21, 2022 Category: Cardiology Authors: Jingyun Tang Jia-Yi Dong Ehab S Eshak Renzhe Cui Kokoro Shirai Keyang Liu Akiko Tamakoshi Hiroyasu Iso JACC study group Source Type: research
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study
Conclusion: This real-world safety analysis found no increase in risk of VTE or other adverse events with use of ospemifene in postmenopausal women.PMID:36420373 | PMC:PMC9677319 | DOI:10.1177/20420986221135931
Source: Cancer Control - November 24, 2022 Category: Cancer & Oncology Authors: Beth L Nordstrom Bin Cai Fabio De Gregorio Lu Ban Kathy H Fraeman Yuki Yoshida Trevor Gibbs Source Type: research
